Literature DB >> 27408380

A Case of Chronic Lymphocytic Leukaemia Occurring During Treatment of Chronic Myeloid Leukaemia.

Marina Dokic1, Ivana Urosevic1, Ivanka Savic2, Borivoj Sekulic2, Aleksandar Savic1, Ivana Milosevic1, Nebojsa Rajic2.   

Abstract

Entities:  

Year:  2016        PMID： 27408380      PMCID： PMC4925548          DOI： 10.1007/s12288-016-0638-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.900


× No keyword cloud information.
  18 in total

1.  Response to dasatinib in a patient with concomitant chronic myeloid leukemia and chronic lymphocytic leukemia.

Authors:  Mariana Serpa; Israel Bendit; Fernanda Seguro; Flavia Xavier; Marcela Cavalcante; Daniel Steinbaum; Luciana Nardinelli; Vera Lucia Aldred; Henrique Moura de Paula; Pedro Enrique Dorlhiac-Llacer
Journal:  Acta Haematol       Date:  2010-08-19       Impact factor: 2.195

2.  c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.

Authors:  John C Allen; Fatima Talab; Mirko Zuzel; Ke Lin; Joseph R Slupsky
Journal:  Blood       Date:  2011-01-10       Impact factor: 22.113

Review 3.  Impairments in immune cell function in B cell chronic lymphocytic leukemia.

Authors:  M M Bartik; D Welker; N E Kay
Journal:  Semin Oncol       Date:  1998-02       Impact factor: 4.929

4.  Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.

Authors:  Dushyant Verma; Hagop Kantarjian; Sara S Strom; Mary Beth Rios; Elias Jabbour; Alfonso Quintas-Cardama; Srdan Verstovsek; Farhad Ravandi; Susan O'Brien; Jorge Cortes
Journal:  Blood       Date:  2011-08-16       Impact factor: 22.113

5.  Solid tumors after chronic lymphocytic leukemia.

Authors:  M Hisada; R J Biggar; M H Greene; J F Fraumeni; L B Travis
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

6.  Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia.

Authors:  Philip C Amrein; Eyal C Attar; Tak Takvorian; Ephraim P Hochberg; Karen K Ballen; Kathleen M Leahy; David C Fisher; Ann S Lacasce; Eric D Jacobsen; Philippe Armand; Robert P Hasserjian; Lillian Werner; Donna Neuberg; Jennifer R Brown
Journal:  Clin Cancer Res       Date:  2011-03-14       Impact factor: 12.531

7.  Case report and literature review: a rare patient with chronic myeloid leukemia and chronic lymphocytic leukemia.

Authors:  Sharathkumar Bhagavathi; Vidal Borromeo; Harsha Desai; Domnita Crisan
Journal:  Ann Clin Lab Sci       Date:  2008       Impact factor: 1.256

8.  Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.

Authors:  Rita M Braziel; Teresa M Launder; Brian J Druker; Susan B Olson; R Ellen Magenis; Michael J Mauro; Charles L Sawyers; Ronald L Paquette; Michael E O'Dwyer
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

Review 9.  Acute lymphoblastic leukemia without the Philadelphia chromosome occurring in chronic myelogenous leukemia with the Philadelphia chromosome.

Authors:  Hee Jin Huh; Jung Won Huh; Chu Myong Seong; Miae Lee; Wha Soon Chung
Journal:  Am J Hematol       Date:  2003-11       Impact factor: 10.047

Review 10.  Dasatinib-responsive chronic lymphocytic leukemia in a patient treated for coexisting chronic myeloid leukemia.

Authors:  Takayo Nagao; Naoto Takahashi; Yoshihiro Kameoka; Shinsuke Noguchi; Yoshinori Shinohara; Hideaki Ohyagi; Masaaki Kume; Kenichi Sawada
Journal:  Intern Med       Date:  2013       Impact factor: 1.271
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.